Active Ingredient: A sterile, clear, colorless solution containing tranexamic acid, a synthetic derivative of the amino acid lysine.
Concentration: Each milliliter of the injection contains 100 milligrams (mg) of tranexamic acid, typically administered intravenously (IV).
Advantages
Rapid Onset of Action: Provides quick hemostatic effects when administered intravenously, making it crucial for urgent control of severe bleeding.
Potent Bleeding Control: Highly effective in reducing or preventing excessive hemorrhage by stabilizing blood clots in various acute and surgical settings.
Uses
Acute Severe Hemorrhage: Used for the treatment of severe bleeding, such as in trauma, postpartum hemorrhage, or gastrointestinal bleeding.
Surgical Prophylaxis: Administered to reduce blood loss and transfusion requirements during and after major surgeries known to cause significant bleeding (e.g., cardiac surgery, orthopedic surgery, prostatectomy).
Nature
Antifibrinolytic Agent: Tranexamic acid primarily acts as an antifibrinolytic agent, meaning it inhibits the dissolution of blood clots.
Mechanism of Action: It functions by competitively inhibiting the activation of plasminogen to plasmin, and to a lesser extent, directly inhibiting plasmin itself. Plasmin is the enzyme responsible for breaking down fibrin (the structural component of blood clots), thus stabilizing the clot and promoting hemostasis.
Storage
Temperature: Store Tranexamic Acid Injection 100 mg/mL at controlled room temperature, typically between 20∘C to 25∘C (68∘F to 77∘F).
Protection & Handling: Keep the vials or ampoules in their original packaging to protect them from light; do not freeze; solutions should be clear and colorless, and any unused portion from a single-dose container must be discarded.
